



FY2027 Q1 Financial Results Summary [Japanese GAAP] (Consolidated)

August 14, 2026

Listed Company Name Kusurinomadoguchi Co., Ltd.

Stock Exchange

TSE

Code Number 5592

URL <https://kusurinomadoguchi.co.jp/>

Representative (Title) Representative Director (Name) Koji Tsutsumi

Contact (Title) Head of General Affairs (Name) Naoto Masuda (TEL) 03-6712-7406

Scheduled dividend payment date -

Supplementary financial results materials : Yes

Investor relations briefing : No

(Rounded down to the nearest million yen)

1. Q1 FY2027 Consolidated Financial Results (April 1, 2026 - June 30, 2026)

(1) Consolidated Financial Results (Cumulative) (% figures represent year-on-year changes)

	Revenue		Operating profit		Ordinary profit		Net income attributable to owners of the parent	
	JPY millions	%	JPY millions	%	JPY millions	%	JPY millions	%
Q1 FY2027	3,643	25.0	784	24.6	778	20.6	623	61.0
Q1 FY2026	2,914	10.8	629	64.5	645	69.9	386	61.4

(Note) Comprehensive income Q1 FY2027 605JPY millions (47.2%) Q1 FY2026 411million yen (82.5%)

	Per share Quarterly net income	Diluted Per share Quarterly net income
	Yen / Sen	Yen / Sen
Q1 FY2027	54.43	54.03
Q1 FY2026	34.47	33.98

(2) Consolidated Financial Position

	Total assets	Net assets	Equity Ratio (%)
	JPY millions	JPY millions	%
Q1 FY2027	18,227	11,456	62.2
FY2026	17,816	11,464	63.7

(Reference) Shareholders' equity Q1 FY2027 11,345JPY millions FY2026 11,352JPY millions

2. Dividends

	Annual dividend per share (Yen)				
	Q1 end	Q2 end	Q3 end	Year-end	Total
	Yen / Sen	Yen / Sen	Yen / Sen	Yen / Sen	Yen
FY2026	-	0.00	-	38.00	38.00
FY2027	-	-	-	-	-
FY2027 (Forecast)	-	0.00	-	40.00	40.00

(Note) Revision from the most recently announced dividend forecast : No

3. Consolidated Earnings Forecast for FY2027 (April 1, 2026 to March 31, 2027)

(% figures represent year-on-year changes)

	Revenue		Operating profit		Ordinary profit		Net income attributable to owners of the parent		EPS (Yen)
	JPY millions	%	JPY millions	%	JPY millions	%	JPY millions	%	Yen
Full year	14,400	16.8	3,100	15.6	3,100	16.3	3,100	5.0	270.53

(Note) Revision from the most recently announced earnings forecast : No

* Notes

(1) Significant changes in the scope of consolidation during the current quarterly consolidated cumulative period : Yes

Added 2companies (Company name) Techno Network Co., Ltd. Excluded -companies (Company name) - Keing Co., Ltd.

The Company acquired all shares of Techno Network Co., Ltd. on May 1, 2026, and accordingly included it in the scope of consolidation. In addition, as a result of Techno Network Co., Ltd. becoming a wholly-owned subsidiary of the Company, Keing Co., Ltd., a wholly-owned subsidiary of Techno Network Co., Ltd., has also been included in the scope of consolidation.

(2) Application of accounting treatments specific to quarterly consolidated financial statements : No

Notes on application of accounting treatments specific to quarterly consolidated financial statements

(3) Changes in Accounting Policies, Changes in Accounting Estimates, and Restatements

- (i) Changes in accounting policies due to revisions to accounting standards : No
- (ii) Changes in accounting policies other than (i) : No
- (iii) Changes in accounting estimates : No
- (iv) Restatement : No

Notes on changes in accounting policies

(4) Number of Shares Issued (Common Shares)

(i) Total shares outstanding at end of period (including treasury shares)

(ii) Treasury shares at end of period

(iii) Average number of shares outstanding during the period (cumulative for the quarter)

Q1 FY2027	11,459,482shares	FY2026	11,458,582shares
Q1 FY2027	69,700shares	FY2026	-shares
Q1 FY2027	11,445,702shares	Q1 FY2026	11,222,910shares

※ Review of quarterly consolidated financial statements by certified public accountant or audit firm : No

※ Notes on appropriate use of earnings forecasts and other special items

The forward-looking statements in this document, including earnings forecasts, are based on information currently available to the Company and certain assumptions that the Company considers reasonable, and the Company makes no guarantee as to the achievement thereof. Actual results may differ materially from forecasts due to a variety of factors.

○ Table of Contents (Attachments)

1. Qualitative Information on Q1 Financial Results	2
(1) Overview of Operating Results	2
(2) Overview of Financial Position	2
(3) Overview of Forward-Looking Information Including Consolidated Earnings Forecast	2
2. Quarterly Consolidated Financial Statements and Notes	3
(1) Quarterly Consolidated Balance Sheet	3
(2) Quarterly Consolidated Statement of Income and Statement of Comprehensive Income	5
Quarterly Consolidated Statement of Income	5
Q1 Cumulative Period	5
Quarterly Consolidated Statement of Comprehensive Income	6
Q1 Cumulative Period	6
(3) Notes to Quarterly Consolidated Financial Statements	7
(Notes on Going Concern Assumption)	7
(Notes on Material Changes in Shareholders' Equity)	7
(Segment Information)	7
(Subsequent Events)	7
(Notes on Cash Flow Statement)	9

1. Qualitative Information on Q1 Financial Results

(1) Overview of Operating Results

During the first quarter of the fiscal year under review, Japan's economy continued to face an uncertain outlook, affected by surging global raw material prices and the impact of the situation in the Middle East.

While the FY2026 social security-related budget increased overall, drug prices were generally revised downward in the pharmaceutical price revision. Dispensing pharmacies face increasing difficulty in securing drug price margins, while also being required to improve operational efficiency and implement DX (digital transformation) of systems, including community-based integrated care systems, family pharmacy initiatives, and online eligibility verification and electronic prescription compatibility.

Against this market backdrop, the Group, which provides various IT and AI-powered services and products in the healthcare sector including dispensing pharmacies, expects favorable conditions to continue.

In light of these business conditions and the Group's circumstances, the Group partially renamed its business segments beginning with the first quarter of the fiscal year under review: the Media Business has been renamed the "Healthcare Automation Business," and the Pre-Disease Prevention Business has been renamed the "Wellness Platform Business." The Everyone's Medicine Box Business and Core Systems Business remain unchanged.

The renaming to the Healthcare Automation Business reflects the Group's intent to address the chronic labor shortage in the healthcare sector stemming from the declining birthrate, aging population, and population decline, by deploying an AI-powered business process automation platform for the healthcare sector that provides end-to-end automation of customer acquisition, reservations, reception, consultations, patient management, billing, and administrative tasks, thereby delivering solutions that fully automate patient flows that were previously siloed.

The renaming to the Wellness Platform Business reflects the Group's intent to build an AI-powered wellness platform, analyze subscribers' health and behavioral data, and deliver personalized health information, consultation recommendations, follow-up care, and preventive healthcare and health management services, connecting insurers and subscribers on a continuous basis to contribute to advancing the insurance business, optimizing medical costs, and creating value.

The Group worked to increase online prescription acceptance counts in the Healthcare Automation Business, increase pharmaceutical distribution volumes (GMV) at dispensing pharmacies and medical institutions in the Everyone's Medicine Box Business, and increase the number of system users in the Core Systems Business—all key management indicators—while also striving to create added value through enhanced data integration across each business.

As a result, for the first quarter of the fiscal year under review (cumulative period), revenue was ¥3,643,937 thousand (up 25.0% year-on-year), operating profit was ¥784,076 thousand (up 24.6% year-on-year), and ordinary profit was ¥778,104 thousand (up 20.6% year-on-year). Net income attributable to owners of the parent was ¥623,010 thousand (up 61.0% year-on-year).

(2) Overview of Financial Position

Current assets at the end of the first quarter of the fiscal year under review decreased by ¥159,508 thousand from the end of the previous fiscal year, to ¥9,931,414 thousand. This was primarily due to a ¥694,806 thousand decrease in cash and deposits resulting from payments of corporate taxes and dividends.

Non-current assets amounted to ¥8,296,530 thousand, an increase of ¥570,468 thousand from the end of the previous fiscal year. This was mainly attributable to a ¥128,530 thousand decrease in software, offset by a ¥326,220 thousand increase in goodwill and a ¥197,805 thousand increase in investment securities included in other non-current assets.

As a result, total assets increased by ¥410,960 thousand from the end of the previous fiscal year, to ¥18,227,944 thousand.

Current liabilities increased by ¥360,441 thousand from the end of the previous fiscal year, to ¥5,564,077 thousand. This was primarily due to a ¥453,499 thousand increase in accounts payable—other.

Non-current liabilities amounted to ¥1,207,117 thousand, an increase of ¥58,375 thousand from the end of the previous fiscal year. This was mainly due to a ¥58,705 thousand increase in long-term loans payable.

As a result, total liabilities increased by ¥418,817 thousand from the end of the previous fiscal year, to ¥6,771,194 thousand.

Net assets decreased by ¥7,856 thousand from the end of the previous fiscal year, to ¥11,456,749 thousand. This was primarily due to a ¥178,887 thousand increase in treasury shares.

(3) Overview of Forward-Looking Information Including Consolidated Earnings Forecast

There are no changes to the full-year earnings forecast.

2. Quarterly Consolidated Financial Statements and Notes

(1) Quarterly Consolidated Balance Sheet

(Thousands of yen)

	Previous fiscal year (March 31, 2026)	Q1 of current fiscal year (June 30, 2026)
Assets		
Current assets		
Cash and deposits	5,203,879	4,509,073
Notes receivable, accounts receivable, and contract assets	4,056,710	4,367,710
Other	834,223	1,058,807
Allowance for doubtful accounts	△3,890	△4,176
Total current assets	10,090,922	9,931,414
Non-current assets		
Property, plant and equipment	141,580	294,285
Intangible assets		
Goodwill	870,451	1,196,671
Software	3,929,164	3,800,634
Other	122,611	168,238
Total intangible assets	4,922,227	5,165,544
Investments and other assets		
Deferred tax assets	1,631,758	1,602,609
Other	1,130,255	1,332,327
Allowance for doubtful accounts	△99,761	△98,236
Total investments and other assets	2,662,252	2,836,699
Total non-current assets	7,726,061	8,296,530
Total assets	17,816,983	18,227,944

(Thousands of yen)

	Previous fiscal year (March 31, 2026)	Q1 of current fiscal year (June 30, 2026)
Liabilities		
Current liabilities		
Notes payable and accounts payable	201,411	184,302
Short-term borrowings	2,000,000	2,000,000
Accounts payable – other	1,339,178	1,792,678
Income taxes payable	153,725	109,892
Provisions	209,391	105,315
Other	1,299,930	1,371,890
Total current liabilities	5,203,636	5,564,077
Non-current liabilities		
Long-term borrowings	821,171	879,876
Other	327,570	327,241
Total non-current liabilities	1,148,741	1,207,117
Total liabilities	6,352,377	6,771,194
Net assets		
Shareholders' equity		
Capital stock	68,864	69,121
Capital surplus	4,759,565	4,759,822
Retained earnings	6,497,517	6,685,231
Treasury shares	–	△178,887
Total shareholders' equity	11,325,947	11,335,287
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	26,647	9,899
Total accumulated other comprehensive income	26,647	9,899
Share acquisition rights	430	427
Non-controlling interests	111,579	111,135
Total net assets	11,464,605	11,456,749
Total liabilities and net assets	17,816,983	18,227,944

(2) Quarterly Consolidated Statement of Income and Statement of Comprehensive Income

Quarterly Consolidated Statement of Income

Q1 Cumulative Period

	(Thousands of yen)	
	Q1 of previous fiscal year (cumulative) (From April 1, 2025 to June 30, 2025)	Q1 of current fiscal year (cumulative) (From April 1, 2026 to June 30, 2026)
Revenue	2,914,636	3,643,937
Cost of revenue	1,226,350	1,544,861
Gross profit	1,688,286	2,099,076
Selling, general and administrative expenses	1,059,091	1,314,999
Operating profit	629,194	784,076
Non-operating income		
Interest and dividend income	1,634	5,497
Equity in earnings of affiliates	8,138	2,795
Other	6,251	2,386
Total non-operating income	16,024	10,680
Non-operating expenses		
Interest expense	54	10,739
Settlement payment	—	4,689
Other	0	1,223
Total non-operating expenses	54	16,653
Ordinary profit	645,165	778,104
Extraordinary losses		
Office relocation expenses	—	4,897
Total extraordinary losses	—	4,897
Quarterly net income before income taxes	645,165	773,206
Income taxes – current	104,423	100,555
Income taxes – deferred	144,103	50,084
Total income taxes	248,527	150,640
Quarterly net income	396,638	622,565
Net income (loss) attributable to non-controlling interests	9,718	△444
Net income attributable to owners of the parent	386,919	623,010

Quarterly Consolidated Statement of Comprehensive Income

Q1 Cumulative Period

	(Thousands of yen)	
	Q1 of previous fiscal year (cumulative) (From April 1, 2025 to June 30, 2025)	Q1 of current fiscal year (cumulative) (From April 1, 2026 to June 30, 2026)
Quarterly net income	396,638	622,565
Other comprehensive income		
Valuation difference on available-for-sale securities	14,944	△16,748
Total other comprehensive income	14,944	△16,748
Quarterly comprehensive income	411,582	605,817
(Breakdown)		
Quarterly comprehensive income attributable to owners of the parent	401,864	606,261
Quarterly comprehensive income attributable to non-controlling interests	9,718	△444

(3) Notes to Quarterly Consolidated Financial Statements

(Notes on Going Concern Assumption)

Not applicable.

(Notes on Material Changes in Shareholders' Equity)

Based on resolutions of the Board of Directors held on June 5, 2026 and June 29, 2026, the Company acquired 69,700 treasury shares. As a result, during the first quarter of the fiscal year under review (cumulative period), treasury shares increased by ¥178,887 thousand, and at the end of the first quarter, treasury shares amounted to ¥178,887 thousand.

(Segment Information)

As the Group operates as a single segment providing solutions for pharmacies, medical institutions, and nursing care facilities, segment information has been omitted.

(Subsequent Events)

(Business Combination through Acquisition)

At a Board of Directors meeting held on July 23, 2026, the Company resolved to acquire all shares of blankpad, Inc. (hereinafter "blankpad") and make it a wholly-owned subsidiary (hereinafter the "Share Acquisition").

1. Overview of Business Combination

(1) Name and business description of acquiree

Acquiree name: blankpad, Inc.

Business description: Comprehensive talent matching platform business based on personality assessment

(2) Primary reasons for the business combination

In Japan's current labor market, labor shortages and recruitment difficulties have become serious social issues. Similarly, in the dispensing pharmacy industry, pharmacist shortages and increasing competition for talent are major operational challenges.

In addition, in recent years, job seekers have shown a growing tendency to prioritize alignment with a company's culture (corporate culture and values)—not only salary and working conditions—when choosing a new employer. For employers as well, recruiting pharmacists who are a good cultural fit and retaining them over the long term is becoming increasingly important from the perspective of stable store operations and continuous patient service delivery.

The Company has a subsidiary, Yakuzaisi Kyuujin Tenshoku, Inc., which operates a pharmacist-focused talent referral business for dispensing pharmacies. The primary purpose of this Share Acquisition is to create business synergies by combining blankpad's business with that of this subsidiary. Specifically, blankpad's analysis functions will be used to analyze the organizational culture of dispensing pharmacy customers, while pharmacists as job seekers will conduct their own personality analyses, thereby visualizing the characteristics of both the company and the individual. By matching based on the results of both analyses, the Company will be able to make optimal proposals to both companies and job seekers, enabling Yakuzaisi Kyuujin Tenshoku, Inc. to more accurately propose pharmacists who match the talent profile sought by pharmacies.

This is expected to improve recruitment matching accuracy and post-joining retention rates at dispensing pharmacies, contributing to the Group's goal of addressing social issues related to human resources in the healthcare sector. In addition, the Company already has business relationships with numerous dispensing pharmacies, including major dispensing pharmacy chains, and is well aware of its

customers' human resource needs. As a result, it will be possible to promptly begin providing talent matching services after completion of the Share Acquisition, which is expected to expand the service lineup for the Company's customers, improve customer satisfaction, increase the number of personality analyses conducted at blankpad, improve matching accuracy, and expand revenues. Furthermore, major dispensing pharmacy chains have shown strong interest in personality analysis not only for recruitment but also for organizational management purposes, such as assessing compatibility between supervisors, subordinates, and colleagues. This diagnostic service is expected to be conducted annually in conjunction with personnel changes and transfers, which would contribute to securing the continuous revenue base (recurring revenue) that has been a challenge for blankpad. In this way, blankpad's analytical technology is expected to expand its applications beyond matching job seekers and companies to also serving as an organizational management tool within corporations. In addition, by leveraging the Company's sales capabilities and distribution channels, the Company plans to approach mid-sized dispensing pharmacy chains in addition to major chains where the service has already been introduced. In this way, by focusing the target customers on the healthcare sector, such as dispensing pharmacies, through the full subsidiaryization, the accumulation of matching data in this sector and the resultant improvement in proposal accuracy will be achieved, and the primary objective and effect of this transaction is to expand the structure capable of providing new value to the Group's customers. The Company highly values blankpad's unique technology, which conducts both individual personality diagnostics and corporate culture analysis at high accuracy and combines both for talent matching. With a track record of implementation at major dispensing pharmacy chains that are already clients of the Company, the Company believes that by exclusively utilizing this technology through the full subsidiaryization via the Share Acquisition, it can secure a competitive advantage in the healthcare sector where competition for talent is intensifying. While blankpad has a short operating history and has continued to incur losses, the Company judges that acquiring tools based on such unique technological capabilities is meaningful for the Group.

(3) Date of business combination

August 1, 2026

(4) Legal form of business combination

Share acquisition

(5) Name of the combined entity

No change.

(6) Percentage of voting rights acquired

100%

(7) Primary basis for determining the acquirer

The Company acquired shares through a cash consideration.

2. Acquisition cost and breakdown by type of consideration

Acquisition consideration	Cash	5 yen
---------------------------	------	-------

Acquisition cost		5 yen
------------------	--	-------

3. Description and amount of primary acquisition-related costs

Due diligence expenses, etc.: ¥1,000 thousand

4. Amount of goodwill generated, reason for generation, amortization method, and amortization period

Not yet determined.

5. Assets acquired and liabilities assumed on the date of business combination and their breakdown

Not yet determined.

(Notes on Cash Flow Statement)

The quarterly consolidated cash flow statement for the first quarter of the fiscal year under review has not been prepared. The following shows depreciation expenses (including amortization of intangible assets other than goodwill) and goodwill amortization for the first quarter of the fiscal year under review.

	Q1 of previous fiscal year (cumulative) (From April 1, 2025 to June 30, 2025)	Q1 of current fiscal year (cumulative) (From April 1, 2026 to June 30, 2026)
Depreciation and amortization	330,692thousands of yen	375,173thousands of yen
Amortization of goodwill	19,672thousands of yen	35,464thousands of yen